KBI Biopharma
Erik Nordwald
Director, Head of Microbial Process Development
Gain an in-depth understanding of KBI Biopharma's flexible and innovative platform technologies, designed to drive next-generation bioprocessing efficiencies.
Overview
Our experts discuss how the mammalian (SUREtechnology Platform™, powered by Selexis®) and microbial (PUREplatform™) End-to-End Cell Line Development solutions, combined with industry-leading analytical capabilities, accelerate the development, process characterization, and manufacturing of mAbs, multispecific Abs, ADCs, fusion proteins, and other recombinant therapeutic proteins.
We also provide insights into PROGRAMview™, our advanced digital collaboration platform, showcasing how it enhances data access and collaboration during process development. This platform supports faster, more informed decision-making, greater transparency, and improved communication, ultimately advancing bioprocess speed and quality.
Key topics:
- Explore how KBI Biopharma’s SUREtechnology Platform™ and PUREplatform™ expression systems streamline the development and manufacturing of complex biotherapeutics, including mAbs, multispecific Abs, ADCs, and fusion proteins.
- Learn how KBI Biopharma’s advanced analytics support process optimization, product characterization, and regulatory requirements more efficiently.
- Discover the features and benefits of PROGRAMview™, KBI Biopharma's digital collaboration platform, designed to enhance transparency and communication throughout process development.
The session includes case studies, a demonstration of PROGRAMview™, and a Q&A with our experts.
Presenter
Shaunak Uplekar
Associate Director of Process Development
Marlee Paulson
PROGRAMview Product Owner
Let's Connect
Interested in learning more about KBI Biopharma? Contact us today.